Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
株式のランク #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
株価
$1.51
最終同期: 2024-08-26
時価総額
$1.12M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Agile Therapeutics, Inc. (AGRX)

カテゴリー

Agile Therapeutics, Inc.(AGRX)の利益
Jun 2024 時点の利益 TTM: $-15.86M
Agile Therapeutics, Inc. の最新の財務報告によると、同社の現在の利益は $-15.86M です。2022 年には $-30.09M の利益を上げ、これは 2021 年の利益 $-74.89M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Agile Therapeutics, Inc. の利益の推移(2012 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-15.86M 9.62%
2023 $-14.47M -51.92%
2022 $-30.09M -59.83%
2021 $-74.89M 44.44%
2020 $-51.85M 178.69%
2019 $-18.61M -8.15%
2018 $-20.26M -28.43%
2017 $-28.30M -11.04%
2016 $-31.82M -12.37%
2015 $-36.31M 84.02%
2014 $-19.73M 37.77%
2013 $-14.32M -38.43%
2012 $-23.26M 0.00%